Overview of Omr

Property	Description
Active Ingredient	Paracetamol, Diclofenac, Chlorzoxazone
Form	Tablet (Oral Administration)
Pharmacological Class	Analgesic, NSAID, Centrally Acting Muscle Relaxant
Common Use	Relief of musculoskeletal pain, spasm, and inflammation
Origin	Synthetic

Omr is a prescription-only, synthetic fixed-dose combination medicine, formulated for oral administration and typically supplied as a tablet. It is intended to manage acute pain and stiffness associated with musculoskeletal conditions. This formulation is distinctive because it targets three separate pain and stiffness pathways simultaneously.

What Type of Medicine is Omr and How is it Classified?

Omr is classified as a multi-component agent belonging to the Analgesic, Nonsteroidal Anti-inflammatory Drug (NSAID), and Centrally Acting Skeletal Muscle Relaxant classes. The Diclofenac component places it within the potent NSAID category, a type of agent that provides strong anti-inflammatory action. The distinct actions of each active ingredient contribute to its overall classification. This combination structure differentiates Omr from simpler, single-agent drugs, as it is designed to manage symptoms—such as muscle strain or chronic tension—that require simultaneous action against pain, inflammation, and muscle rigidity.

Omr’s Composition: Active Ingredients and Differentiation

Omr is composed of three principal synthetic active ingredients: Paracetamol (Acetaminophen), Diclofenac, and Chlorzoxazone. This specific three-component formulation is commonly offered by manufacturers under various alternative brand names like Dualscan MR or Zac MR, reflecting its use as a compound treatment for muscle stiffness. The formulation combines a centrally acting agent, such as Chlorzoxazone, with an analgesic like Paracetamol for conditions involving muscle stiffness. The composition utilizes the NSAID action of Diclofenac for anti-inflammatory effects, while Chlorzoxazone acts on the central nervous system to reduce excessive muscle spasm.

What is the General Purpose of Omr?

The general purpose of Omr is to provide comprehensive relief from symptoms associated with acute muscle-related discomfort, including muscle spasm, pain, and swelling. By combining components that reduce underlying tissue inflammation and alleviate involuntary muscle rigidity, the medicine is designed to manage the complex discomfort that arises when muscle tightness and tissue reaction co-occur. This approach is focused on improving patient comfort and assisting in restoring normal muscle movement and function following an acute event.

Therapeutic Uses of Omr

Omr is a supportive therapeutic option designed to manage symptoms related to physical discomfort that commonly cluster in acute musculoskeletal conditions. It provides a multi-faceted approach to symptomatic relief across domains, aiding patients during periods of heightened discomfort. The combination is intended for easing symptoms that interfere with daily functioning as part of symptomatic management.

The medication addresses symptoms of involuntary muscle spasm and associated rigidity, alongside acute pain and localized inflammation. It is commonly used across conditions presenting with acute episodes, such as muscle strains, ligament sprains, discomfort related to tendonitis, and acute flare-ups of low back pain.

“This supportive action contributes to easing the overall symptom load and helps improve day-to-day comfort during periods of heightened symptoms.”

Omr is applied in contexts where supportive symptom management is appropriate following a specific traumatic event or certain surgical procedures. By easing muscle rigidity and pain, the treatment supports the patient during difficult episodes by easing distress, and assists with maintaining functional stability during symptomatic phases.

Focus on Symptomatic Relief: Pain, Spasm, and Inflammation

Eligibility and Restrictions for Use

Who Can and Cannot Use Omr

Omr (Diclofenac, Paracetamol, Chlorzoxazone Fixed-Dose Combination) is officially intended for adults who do not possess specific contraindications, according to regulatory documents.

Contraindicated Populations (Must Not Use)

Population Group	Regulatory Status
Known hypersensitivity to any component (NSAID, analgesic, muscle relaxant) or excipient	Contraindicated
History of asthma or allergic reactions to aspirin or other NSAIDs	Contraindicated
Patients with active gastrointestinal ulceration, bleeding, or perforation	Contraindicated
Patients with severe heart, hepatic, or renal failure	Contraindicated
Patients in the setting of coronary artery bypass graft (CABG) surgery	Contraindicated
Women in the third trimester of pregnancy (after 30 weeks gestation)	Contraindicated

Age and Physiological Restrictions

Population Group	Eligibility Status
Children under 12 years	Not Recommended
Elderly patients	Restricted/Caution Required
Women who are breastfeeding	Not Recommended
Patients with impaired cardiac or renal function	Restricted/Caution Required

Regulatory criteria define this medicine's use by excluding specific populations due to the risks associated with the NSAID (Diclofenac) and Paracetamol components. Use in children, pregnant women, and breastfeeding women is generally not recommended or is strictly prohibited, limiting the medicine's scope to non-vulnerable adult patients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of this medicine is structured around the documented risks associated with its three active components: Paracetamol, Diclofenac, and Chlorzoxazone. Official regulatory labels identify specific pharmacokinetic and pharmacodynamic interactions that restrict co-administration with certain substances.

Documented Pharmacodynamic and Toxicological Interactions

Interacting Substance Category	Official Regulatory Restriction or Outcome
Other Paracetamol Products	Must not be co-administered due to the severe risk of Paracetamol overdose and associated hepatotoxicity.
Other NSAIDs (e.g., Aspirin)	Co-administration is not recommended due to the increased risk of gastrointestinal adverse events, including bleeding and ulceration.
Alcohol and CNS Depressants	Co-ingestion or co-administration may result in additive central nervous system depression, increasing effects like sedation.
Anticoagulants (e.g., Warfarin)	Increased risk of bleeding due to interference with blood clotting mechanisms.

Pharmacokinetic and Exposure Alterations

Substances that inhibit the CYP2C9 metabolic pathway, such as Voriconazole, may increase the plasma concentration of Diclofenac. Conversely, certain agents like Metoclopramide or Domperidone may increase the rate of Paracetamol absorption, while Cholestyramine reduces the absorption rate. Diclofenac is also officially documented to increase the plasma concentrations of co-administered medicines such as Lithium and Digoxin. Furthermore, its co-administration may diminish the antihypertensive effect of medicines like ACE Inhibitors and ARBs.

Mechanism of Action

OMR (Omarigliptin) is an oral inhibitor that modulates key enzyme and signaling pathways. Its primary mechanism centers on the incretin system and the modulation of specific receptors and enzymatic cascades.

Enzyme-Mediated Signaling Modulation

OMR acts as an inhibitor of the Dipeptidyl Peptidase-4 (DPP-4) enzyme. By blocking this enzyme's activity, the drug prevents the rapid degradation of incretin hormones such as GLP-1 and GIP, increasing their circulating concentrations. This modification results in the presence of non-degraded pathway mediators.

Incretin Pathway Mediator Action

The elevated levels of intact, active incretin hormones engage their respective receptors on target cells. This receptor binding activates cAMP-dependent signaling pathways within the cell, leading to distinct intracellular processes and subsequent downstream functional consequences.

Receptor Engagement in the Central System

OMR also shows binding affinity for the A2A adenosine receptor, a target involved in regulating neurotransmitter release. OMR engages non-canonical mechanisms that influence signaling within systems expressing the A2A adenosine receptor.

Dosage and Administration Information

How to Use Omr

Omr is a fixed-dose combination medicine approved for oral administration as a tablet. The administration regimen for adults generally consists of one tablet taken up to two to three times daily. The tablet should be swallowed whole with liquid and must not be crushed, chewed, or broken before ingestion. It is typically advised to take the medicine with food or meals.

Dosage and Duration Principles

The usage of this combination product is based on the principle of employing the lowest effective dose for the shortest duration necessary to manage symptoms. This approach is consistent with established guidelines for NSAID-containing medicines. The standard single dose delivers Diclofenac 50 mg, Paracetamol 325 mg, and Chlorzoxazone 250 mg.

Population-Specific Administration

General prescribing principles include high-level advice for specific populations. For frail older adults or those with a low body weight, the use of the lowest effective dose is particularly advised. If a regular dose is missed, it should be skipped if the next dose is due soon; a double dose must not be taken to compensate for the skipped one. For patients undergoing prolonged therapy, monitoring of hepatic and renal function is generally indicated.

Recent Clinical Evidence

Omr: Recent Clinical Evidence

Overview of Clinical Research

Research has examined the compound's use in individuals with mild-to-moderate knee osteoarthritis (OA). Studies have explored the proposed action of the compound. Research has examined effects related to joint function and reported pain in individuals with mild-to-moderate knee OA.

Primary Efficacy Findings

WOMAC Score Analysis

Studies evaluated changes in Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores over a 6-month period. The WOMAC Index was used to evaluate pain, stiffness, and physical function in OA research. Research focused on how the compound performed on these three components. Findings from randomized trials examined the overall WOMAC scores compared to a placebo.

Pain and Function

Clinical activity was studied for its potential relevance to flare-ups. Some research has explored the impact of co-administering this compound with physical therapy. Studies explored whether the combination may be associated with changes in mobility and the use of rescue analgesics. Research has not extensively investigated morning stiffness.

Safety and Tolerability Profile

Adverse Events

Studies have investigated the side effect profile of the compound. Studies explored the side effect profile and monitored the compound's tolerability over extended periods.

Contraindications and Interactions

Studies have investigated the response across different age groups. Researchers observed the time to initial change.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Omr (FAQ)

Q: What is Omr used for?

A: Omr (omacetaxine mepesuccinate) is a prescription medicine used to treat adults with Chronic Myeloid Leukemia (CML). Specifically, it is used for CML that is resistant to or intolerant of at least two prior tyrosine kinase inhibitors (TKIs). It is a type of chemotherapy that works by inhibiting protein synthesis within cancer cells.

Q: How is Omr given?

A: Omr is given by injection under the skin (subcutaneously). It is typically administered by a healthcare provider in a clinic or hospital setting. The medication is given in two phases: the induction phase and the maintenance phase. The dosing schedule and length of treatment depend on how the patient responds to the drug and is determined by the healthcare provider.

Q: What are the common side effects of Omr?

A: The most common side effects of Omr can include low blood cell counts (such as low platelet counts, low white blood cell counts, and anemia), nausea, fatigue, diarrhea, injection site reactions, and fever. Patients should inform their doctor immediately if they experience signs of infection (fever, chills) or unusual bleeding or bruising.

Q: Can Omr affect blood cell counts?

A: Yes, Omr can cause a significant decrease in blood cell counts, including platelets (thrombocytopenia), neutrophils (neutropenia), and red blood cells (anemia). These conditions can increase the risk of bleeding or infection. Blood counts will be monitored regularly during treatment, and dosing may be adjusted if blood cell counts become too low.

Q: What should I tell my doctor before starting Omr?

A: Before starting Omr, tell your doctor about all your medical conditions, including if you have liver or kidney problems, or any heart problems. Also, inform your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements, as they may interact with Omr. If you are pregnant, planning to become pregnant, or breastfeeding, discuss this with your doctor.

Q: Can Omr be taken during pregnancy?

A: Omr may cause harm to an unborn baby. Women who are able to become pregnant should use effective contraception during treatment and for a period of time after the last dose. Men with female partners who are able to become pregnant should also use effective contraception during treatment and after the last dose. It is essential to discuss family planning and the potential risks to the fetus with a healthcare provider before starting treatment.

Q: What should I do if I miss a dose of Omr?

A: If a dose of Omr is missed, contact your healthcare provider immediately for instructions. Do not double the dose to make up for a missed one. Your doctor will advise on the appropriate next step based on your individual treatment schedule.

Q: What is the difference between the induction and maintenance phases of Omr treatment?

A: The induction phase is the initial period of treatment, typically lasting a short time, during which Omr is given more frequently to rapidly reduce the number of leukemia cells. The maintenance phase follows the induction phase and involves less frequent dosing to maintain the treatment response over a longer period. The goal of the maintenance phase is to keep the leukemia under control.

How should Omr be stored and disposed of?

Official Storage and Disposal Requirements for Omr

The medicine Omr (Paracetamol, Diclofenac, Chlorzoxazone tablets) must be stored and disposed of according to specific regulatory guidelines to maintain its stability and ensure safety.

Storage Conditions

Temperature and Environment: Omr tablets must be stored below 30°C (86°F) in a cool and dry place, ensuring protection from moisture and light. The tablets must not be frozen.
Packaging and Safety: The medicine should remain in its original container and be kept securely closed. It is mandatory to store Omr out of the sight and reach of children.

Disposal Instructions

Any unused or expired Omr product must be disposed of in accordance with local and national regulations. To protect the environment, the medicine must not be released into wastewater or household waste; consult a pharmacist or local authority for approved disposal methods.

Omr

Omr

Medically reviewed